NCT00313456View on ClinicalTrials.gov

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

TumorsProstate Cancer

Interventions

DRUG

Satraplatin

Satraplatin is an oral platinum analogue that has shown promising activity in multiple tumor settings. Satraplatin (40 to 80 mg/m2/day) will be administered orally on days 1 to 5 of a 21 day cycle.

Trial Locations (1)

Unknown

Sarah Cannon Research Institute, Nashville